home / stock / cydy / cydy news

CYDY News and Press, CytoDyn Inc From 04/05/21

Stock Information
Company Name: CytoDyn Inc
Stock Symbol: CYDY
Market: OTC
Website: cytodyn.com
Menu
CYDY CYDY Quote CYDY Short CYDY News CYDY Articles CYDY Message Board
Get CYDY Alerts

News, Short Squeeze, Breakout and More Instantly...
CYDY - CytoDyn updates on leronlimab-treated COVID-19 patient

Late March, CytoDyn ([[CYDY]] +24.5%) announced that the Philippines FDA approved the use of Vyrologix (leronlimab) to treat a COVID-19 patient under compassionate special permit.38 hours after the subcutaneous injection of leronlimab, the patient has ‘significantly’ i...
CYDY - CytoDyn Completes $28.5 Million Convertible Note Financing with Conversion Rate at $10.00 Per Share Without Warrants to Accelerate Manufacturing of Leronlimab Inventory

VANCOUVER, Washington, April 05, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, annou...

CYDY - First Compassionate Special Permit (CSP) Patient in Philippines Improved Significantly 35 hours After First Injection of Leronlimab and Released 3 Days Later

VANCOUVER, Washington, April 05, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic ...

CYDY - CytoDyn to provide full update on its activities on April 6

CytoDyn (CYDY) will host an investment community webcast on Tuesday, April 6, 2021 at 4:00 pm ET. Management will provide a full update on Company activities, including recent COVID-19 initiatives and information on active trials in COVID-19, NASH and cancer. Management will provide appr...
CYDY - CytoDyn to Hold Webcast on April 6 to Provide a Full Update on Its Activities

VANCOUVER, Washington, April 01, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic ...

CYDY - CytoDyn files new protocol with FDA for 4 doses of leronlimab for critical COVID-19

After several weeks of discussions with the FDA and analysis of CD12 trial data, CytoDyn (CYDY) has filed a new protocol for leronlimab to extend treatment to four weeks.The Company believes four weeks of leronlimab treatment to be sufficient to calm the cytokine storm and to have a posi...

CYDY - CytoDyn Files New Protocol with U.S. FDA for 4 Doses of Leronlimab for Critically Ill COVID-19 Patients with the Objective to Duplicate or Surpass 82% Survival Benefit with P-Value of 0.0233 Originally Achieved from Two Weeks of Treatment in CD12 Trial Wi

Trial commencement will be expedited by enrolling patients in Brazil, U.K., and Canada while immediate EUA requests are pursued in multiple countries VANCOUVER, Washington, April 01, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Com...
CYDY - CYDY Reminder: Kessler Topaz Meltzer & Check, LLP - Deadline Reminder for CytoDyn Inc. Investors

RADNOR, Pa., March 31, 2021 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP reminds CytoDyn Inc. (OTCMKTS: CYDY) (“CytoDyn”) investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Western Dis...

CYDY - CytoDyn's Leronlimab Decreased Mortality at 14 Days by 82% With Statistically Significant P-Value of 0.0233 Amongst Critically Ill COVID-19 Patients

Clinical outcome improvement (based on ordinal scale) with leronlimab at day 14 was 400% better than placebo arm with p-value of 0.021 VANCOUVER, Washington, March 30, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or the "Company"), a late-stage biotechnolog...

CYDY - Philippines OKs use of CytoDyn's leronlimab in COVID-19

CytoDyn (CYDY) announces that the Republic of the Philippines, Department of Health, Food and Drug Administration has approved the use of leronlimab to treat a COVID-19 patient under Compassionate Special Permit ((CSP)) pursuant to FDA Order No. 2016-005. The Company is shipping leronlimab to...
Previous 10 Next 10